- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Expert Opin Drug Discov. 2016 Oct 31. [Epub ahead of print]
The current status and future directions of hepatitis B antiviral drug discovery.
Tang L1, Zhao Q2, Wu S2, Cheng J2, Chang J2, Guo JT2.
Author information
1a Microbiology and Immunology graduate program , Drexel University College of medicine , 3805 Old Easton Road, Doylestown , PA 18902 , USA.
2b Baruch S. Blumberg Institute , Hepatitis B foundation , 3805 Old Easton Road, Doylestown , PA 18902 , USA.
Abstract
INTRODUCTION:
The current standard care of chronic hepatitis B fails to induce a durable off-drug control of hepatitis B virus (HBV) replication in the majority of treated patients. The primary reasons are its inability to eliminate the covalently closed circular (ccc) DNA, the nuclear form of HBV genome, and restoration of the dysfunctional host antiviral immune response against the virus. Accordingly, discovery and development of therapeutics to completely stop HBV replication, eliminate or functionally inactivate cccDNA as well as activate a functional antiviral immune response against HBV are the primary efforts for finding a cure for chronic hepatitis B. Area covered: Herein, the authors highlight the current efforts of HBV drug discovery and offer their opinions for the future directions of this research. Expert opinion: The authors believe that through a consecutive or overlapping three-stage antiviral and immunotherapy program to: (i) completely stop HBV replication and cccDNA amplification; (ii) reduce viral antigen load and induce HBV surface antigen (HBsAg) seroclearance through eradication or inactivation of cccDNA and RNA interference-mediated degradation of viral mRNA and (iii) activate a functional antiviral immune response against HBV through therapeutic immunization or immunotherapy, a functional cure of chronic HBV infection can be achieved in the majority of chronic HBV carriers.
|
|